Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

(Yicai) Jan. 3 -- US pharma giant Eli Lilly’s Tirzepatide injection for blood sugar control and weight loss is now available ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The FDA has approved Eli Lilly’s obesity drug, Zepbound (tirzepatide), as the first treatment for obstructive sleep apnea in the U.S. The Food and Drug Administration (FDA) has reaffirmed its ...

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...